Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.32 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.32 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | NOS2 | P35228 | 2/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.30 |
| ▸ | ITGAV | P06756 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9569994 | 0.86 | METAP2 (0.42) | METAP2METAP1NPY5RPI4KAPI4K2B | |
| SCHEMBL6485 | 0.83 | METAP2 (0.42) | METAP2METAP1NPY5RPI4KAPI4K2B | |
| SCHEMBL29208955 | 0.83 | METAP2 (0.42) | METAP2METAP1NPY5RPI4KAPI4K2B | |
| SCHEMBL30884953 | 0.83 | METAP2 (0.42) | METAP2METAP1NPY5RPI4KAPI4K2B | |
| SCHEMBL9936013 | 0.82 | METAP2 (0.44) | METAP2METAP1NPY5RENPP1ITGB3 | |
| SCHEMBL7073073 | 0.80 | RAD52 (0.42) | METAP2METAP1NPY5RPI4KAPI4K2B | |
| SCHEMBL7851163 | 0.80 | PI4KA (0.49) | METAP2METAP1NPY5RPI4KAPI4K2B | |
| SCHEMBL3691689 | 0.79 | PI4KA (0.55) | METAP2METAP1PI4KAPI4K2BPI4K2A | |
| SCHEMBL5062499 | 0.79 | METAP2 (0.39) | METAP2METAP1NPY5RPI4KAPI4K2B | |
| SCHEMBL235437 | 0.79 | CACNA1H (0.41) | METAP2METAP1NPY5RPI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1060182-B1 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-7351399-B2 | Prodrugs for phosphorus-containing compounds | METABASIS THERAPEUTICS, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20050288240-A1 | Novel-prodrugs for phosphorus-containing compounds | ERION MARK D | 2005-12-29 | — | — | US | disclosed |
| US-6946115-B2 | Prodrugs for phosphorus-containing compounds | METABASIS THERAPEUTICS, INC. (US) | 2005-09-20 | — | — | US | disclosed |
| US-20020052345-A1 | Novel prodrugs for phosphorus-containing compounds | METABASIS THERAPEUTICS, INC. | 2002-05-02 | — | — | US | disclosed |
| US-6312662-B1 | CONVERSION BY HUMAN LIVER MICROSOMES TO MPO3H2 | METABASIS THERAPEUTICS, INC. | 2001-11-06 | — | — | US | disclosed |
| EP-1060182-A2 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | Metabasis Therapeutics, Inc. (US) | 2000-12-20 | — | — | EP | disclosed |
| WO-1999045016-A9 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS INC (US) | 2000-03-02 | — | — | WO | disclosed |
| WO-1999045016-A2 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS, INC. (US) | 1999-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288240-A1 | Novel-prodrugs for phosphorus-containing compounds | HCRTR2, CYP2R1, SLC22A8 | METAP2 2944/4885METAP1 4586/4885NPY5R 1144/4885 |
| US-20020052345-A1 | Novel prodrugs for phosphorus-containing compounds | CCRL2, CCR4, ALK | METAP2 3721/4885METAP1 4276/4885NPY5R 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.